The vice president and lead of IQVIA's Market Access Center of Excellence says fewer drugs are hitting the $100 million mark ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Shares of Centene Corp. advanced 3.09% to $59.47 Monday, on what proved to be an all-around positive trading session for the ...

IQVIA™ (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence ...

Fintel reports that on April 25, 2025, HSBC downgraded their outlook for IQVIA Holdings (NYSE:IQV) from Buy to Hold. Analyst ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $227.67, ...

HSBC analyst Sidharth Sahoo downgraded Iqvia (IQV) to Hold from Buy with a price target of $160, down from $260. The firm adjusted ratings in ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

The stock's rise snapped a four-day losing streak.

IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, announced today that the global independent research and analysis firm ...

Board Certified in Endocrinology, Diabetes, and Metabolism and Internal Medicine, Dr. Caveney leads IQVIA’s Obesity, ...

IQVIA Hldgs (NYSE:IQV) underwent analysis by 12 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. In the table below, you'll find a summary of their recent ...